Lichen China
LICN
1 hedge funds and large institutions have $1.3K invested in Lichen China in 2023 Q4 according to their latest regulatory filings, with funds opening new positions, increasing their positions, 1 reducing their positions, and 0 closing their positions.
0% more funds holding
Funds holding: 1 → 1 (0)
0% less ownership
Funds ownership: 0% → 0% (-0%)
51% less capital invested
Capital invested by funds: $2.66K → $1.3K (-$1.36K)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$2.42K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
UBS Group
Zurich,
Switzerland
| $1.3K | -$2.42K | -8 | -73% |
|
LICN Hedge Fund Activity: Q4 2023 in Review
1 of the 6,860 institutional investors tracked by Wall St. Rank reported a position in Lichen China (LICN) for Q4 2023, worth a combined $1.3K — down 51% from $2.66K a quarter earlier.
Fund positioning in LICN was balanced in Q4 2023: 0 funds opened new positions, 0 closed out, 0 added to existing stakes and 1 trimmed.
The largest seller was UBS Group, cutting an estimated $2.42K.
- 1 institutional investor held Lichen China (LICN) as of Q4 2023, unchanged from Q3 2023.
- Funds reported $1.3K of Lichen China stock for Q4 2023, down 51% quarter-over-quarter.
- 0 funds opened new Lichen China positions in Q4 2023 and 0 closed out.
- The largest Lichen China seller in Q4 2023 was UBS Group, an estimated $2.42K sold.
Based on aggregated 13F filings for Q4 2023.